The global prosthetic heart valve market is anticipated to grow at a considerable CAGR of 9% during the forecast period. The increasing approvals for the various advanced heart valve by the FDA and other organizations are contributing to the growth of the global market. Various companies such as Medtronic PLC, Boston Scientific Corp., Abbott Laboratories Inc., and others received approval for their advanced heart valves as these companies can commercialize their products and gain a strong position in the market. For instance, in September 2021, Abbott announced that the US Food and Drug Administration (FDA) approved the company’s Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease.
A full report of Prosthetic Heart Valves Market is available at: https://www.omrglobal.com/industry-reports/prosthetic-heart-valve-market-size
These next-generation devices build off Abbott’s Epic surgical valve platform, which has a decades-long history of safety and strong clinical outcomes– and includes innovations that make implantation of the valve and future cardiac interventions easier. In addition, More than 100,000 people in the U.S. have conventional heart valve surgeries each year, which are often life-saving procedures. The approval of the new Epic Plus tissue valves provides an important treatment option for patients undergoing valve replacement surgery without the need for long-term blood thinners while providing a durable solution that allows for reinterventions as needed.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/prosthetic-heart-valve-market-size
Moreover, in March 2021, the US FDA approved the first in the world non-surgical heart valve to treat pediatric and adult patients with a native or surgically-repaired right ventricular outflow tract (RVOT), the part of the heart that carries blood out of the right ventricle to the lungs. The device is designed for patients who have severe pulmonary valve regurgitation (blood leaking backward into the right lower chamber of the heart), a condition that often results from congenital heart disease. The use of the Harmony valve may delay the time before a patient needs additional open-heart surgery. It can also potentially reduce the total number of open-heart surgeries required over an individual’s lifetime.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
o By Type
o By End-Users
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- including Cardiosolutions, Inc. (Ingenovis Health), Colibri Heart Valve LLC, enVVeno Medical Corp., HLT, Inc., and others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Prosthetic Heart Valves Market Report Segment
By Type
- Mechanical Heart Valves
- Biological/Tissue Heart Valves
By End-Users
- Hospitals
- Ambulatory Centers
